These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 22896673)
1. Balancing tissue and tumor formation in regenerative medicine. Bailey AM Sci Transl Med; 2012 Aug; 4(147):147fs28. PubMed ID: 22896673 [TBL] [Abstract][Full Text] [Related]
2. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Mason C; Manzotti E Regen Med; 2010 May; 5(3):307-13. PubMed ID: 20455641 [No Abstract] [Full Text] [Related]
3. Designing regenerative biomaterial therapies for the clinic. Pashuck ET; Stevens MM Sci Transl Med; 2012 Nov; 4(160):160sr4. PubMed ID: 23152328 [TBL] [Abstract][Full Text] [Related]
4. Considerations for tissue-engineered and regenerative medicine product development prior to clinical trials in the United States. Lee MH; Arcidiacono JA; Bilek AM; Wille JJ; Hamill CA; Wonnacott KM; Wells MA; Oh SS Tissue Eng Part B Rev; 2010 Feb; 16(1):41-54. PubMed ID: 19728784 [TBL] [Abstract][Full Text] [Related]
5. Tissue engineering and regenerative medicine: role of toxicologic pathologists for an emerging medical technology. Jayo MJ; Watson DD; Wagner BJ; Bertram TA Toxicol Pathol; 2008 Jan; 36(1):92-6. PubMed ID: 18337226 [TBL] [Abstract][Full Text] [Related]
6. The government's role in advancing regenerative medicine and tissue engineering - science, safety, and ethics. Smith DS Periodontol 2000; 2006; 41():16-29. PubMed ID: 16686924 [No Abstract] [Full Text] [Related]
7. 3Rs of animal testing for regenerative medicine products. Robinson R Sci Transl Med; 2011 Dec; 3(112):112fs11. PubMed ID: 22158858 [TBL] [Abstract][Full Text] [Related]
8. [Regulatory aspect of regenerative medicine/cell therapy: focused on non-clinical studies]. Matsuyama A Rinsho Ketsueki; 2012 Oct; 53(10):1801-7. PubMed ID: 23037754 [No Abstract] [Full Text] [Related]
9. In vitro human tissue models--moving towards personalized regenerative medicine. Schenke-Layland K; Nerem RM Adv Drug Deliv Rev; 2011 Apr; 63(4-5):195-6. PubMed ID: 21600252 [TBL] [Abstract][Full Text] [Related]
10. Regenerative medicine. The industry comes of age. Mason C Med Device Technol; 2007; 18(2):25-30. PubMed ID: 17494498 [TBL] [Abstract][Full Text] [Related]
11. Regenerative medicine strategies. Atala A J Pediatr Surg; 2012 Jan; 47(1):17-28. PubMed ID: 22244387 [TBL] [Abstract][Full Text] [Related]
12. From tissue engineering to regenerative medicine--the potential and the pitfalls. Schenke-Layland K Adv Drug Deliv Rev; 2011 Apr; 63(4-5):193-4. PubMed ID: 21515319 [No Abstract] [Full Text] [Related]
14. Challenges in tissue engineering and regenerative medicine product commercialization: building an industry. Hellman KB; Johnson PC; Bertram TA; Tawil B Tissue Eng Part A; 2011 Jan; 17(1-2):1-3. PubMed ID: 20726818 [No Abstract] [Full Text] [Related]
15. The LOEX perspective on the role of tissue engineering in regenerative medicine. Auger FA Biomed Mater Eng; 2006; 16(4 Suppl):S19-25. PubMed ID: 16823109 [No Abstract] [Full Text] [Related]
16. Mesenchymal stem cells for tissue engineering and regenerative medicine. Tae SK; Lee SH; Park JS; Im GI Biomed Mater; 2006 Jun; 1(2):63-71. PubMed ID: 18460758 [TBL] [Abstract][Full Text] [Related]
17. Tissue engineering and regenerative medicine: manufacturing challenges. Williams DJ; Sebastine IM IEE Proc Nanobiotechnol; 2005 Dec; 152(6):207-10. PubMed ID: 16441181 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic cell delivery for in situ regenerative medicine. Wang DA; Mahato RI Adv Drug Deliv Rev; 2010 Jun; 62(7-8):669-70. PubMed ID: 20420868 [No Abstract] [Full Text] [Related]